Large clinical trials and several reports revealed that PPARα activation by an agonist has protective effects against DR in type 2 diabetes patients10,11, although the mechanisms of action of the PPARα agonist were unclear. This evidence concerns the gene PPARA and type 2 diabetes mellitus.